Sector
PharmaceuticalsOpen
₹845.55Prev. Close
₹845.25Turnover(Lac.)
₹3,227.2Day's High
₹850Day's Low
₹820.152 Week's High
₹901.952 Week's Low
₹394.62Book Value
₹699.58Face Value
₹10Mkt Cap (₹ Cr.)
7,620.01P/E
128.69EPS
6.42Divi. Yield
0.4822 May 2024
12:00 AM
Dividend
Dividend Amount: 2.5
Record Date: 09 Sep, 2024
5 Sep 2024
12:00 AM
AGM
Announcement Date: 05 Sep, 2024
15 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
8 Aug 2024
12:00 AM
EGM
EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.
EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.
In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.
The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.
The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 92.02 | 107.4 | 90.2 | 89.68 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,469.1 | 3,347.65 | 3,316.49 | 3,158.38 |
Net Worth | 3,561.12 | 3,455.05 | 3,406.69 | 3,248.06 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1,857.56 | 1,674.14 | 1,469.6 | 1,381.81 |
yoy growth (%) | 10.95 | 13.91 | 6.35 | -37.8 |
Raw materials | -988.87 | -887.97 | -781.25 | -734.46 |
As % of sales | 53.23 | 53.04 | 53.16 | 53.15 |
Employee costs | -272.72 | -221.76 | -224.53 | -228.47 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 111.63 | 151.85 | 193.51 | 197.8 |
Depreciation | -99.34 | -91.62 | -77.8 | -70 |
Tax paid | -33.39 | -40.15 | -7.68 | -30.71 |
Working capital | 95.65 | 115.9 | -16.3 | -240.87 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.95 | 13.91 | 6.35 | -37.8 |
Op profit growth | -24.18 | 6.56 | 15.44 | -36.73 |
EBIT growth | -19.03 | -20.65 | 2.11 | -2.27 |
Net profit growth | -29.95 | -87.47 | 721.46 | -16.63 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 4,565.34 | 3,890.13 | 3,688.39 | 3,070.25 | 3,315.87 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,565.34 | 3,890.13 | 3,688.39 | 3,070.25 | 3,315.87 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 3,313.33 | 89.29 | 108.9 | 131.99 | 108.72 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman & M.D.
Arun Kumar
Company Sec. & Compli. Officer
Manjula Ramamurthy
Non-Exec. & Independent Dir.
Homi Rustam Khusrokhan
Managing Director & Group CEO
Badree Komandur
Non-Exec. & Independent Dir.
Kausalya Santhanam
Non-Exec. & Independent Dir.
Subir Chakraborty
Non-Exec. & Independent Dir.
Ameet Hariani
Director (Business Developmnt)
Aditya Kumar
Independent Director
Mukta Malik Arora
No 201 Devavrata Sector 17,
Vashi,
Maharashtra - 400703
Tel: 91-22-27892924/27893199
Website: http://www.strides.com
Email: investors@strides.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Strides Pharma Science Limited was originally incorporated under the name Strides Arcolab Limited on June 28, 1990. In FY 2016, Shasun Pharmaceuticals Limited merged with Strides Arcolab Limited form...
Read More
Reports by Strides Pharma Science Ltd
What is the Strides Pharma Science Ltd share price today?
What is the Market Cap of Strides Pharma Science Ltd?
What is the PE and PB ratio of Strides Pharma Science Ltd?
What is the 52 Week High and Low of Strides Pharma Science Ltd?
What is the CAGR of Strides Pharma Science Ltd?
What is the shareholding pattern of Strides Pharma Science Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
